About Britannia Pharmaceuticals
Britannia Pharmaceuticals is a Healthcare company based in Reading (United Kingdom) founded in 1981. Treatments for CNS diseases, particularly Parkinsons, are developed and marketed. It operates on a Direct-to-Consumer (D2C) model. The company has 96 employees. Its chief executive, as recorded, is Robert Wood. Britannia Pharmaceuticals offers products and services including Parkinson’s Disease Therapies, Schizophrenia Treatments, and Nephrology Solutions. Its focus areas include Pharmaceuticals and Specialty Pharmaceuticals. Its legal entity is Britannia Pharmaceuticals Limited.
Company details
Britannia Pharmaceuticals Limited is engaged in the development and provision of innovative specialty therapies aimed at improving disease management and quality of life for patients with long-term neurological conditions such as Parkinsons disease and schizophrenia, as well as nephrology. The company is involved in funding clinical trials, supporting treatment programs, and investing in care initiatives for patients, families, and caregivers. Operating as part of the STADA Group, Britannia serves over 30 countries worldwide, delivering high-quality, ethical treatments and services across various therapeutic areas.
- Headquarters Reading, United Kingdom
- Employees 96
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website britannia-pharm.co.uk
- Social LinkedIn
- Legal Name Britannia Pharmaceuticals Limited
- Annual Revenue$90.92 M (USD)12as on Dec 31, 2020
- Net Profit$34.57 M (USD)15as on Dec 31, 2020
- Employee Count96
Products & Services of Britannia Pharmaceuticals
Britannia Pharmaceuticals offers a comprehensive portfolio of products and services, including Parkinson’s Disease Therapies, Schizophrenia Treatments, and Nephrology Solutions.
Therapies for Parkinson’s disease management are provided here.
Treatments for schizophrenia are developed and offered widely.
Solutions for nephrology conditions are developed and supplied.
People of Britannia Pharmaceuticals
1 people are tracked at Britannia Pharmaceuticals (1 in leadership); the tracked headcount is 96.
| Name | Role | Group |
|---|---|---|
Robert Wood | CEO & MD | Leadership |
Complete people profiles for Britannia Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Web traffic of Britannia Pharmaceuticals
The website of Britannia Pharmaceuticals (britannia-pharm.co.uk) receives about 2K visits a month and ranks #7,663,681 among all websites worldwide, #7,104 in Biotechnology and Pharmaceuticals.
- Monthly visits2K
▲ 3% vs previous month
- Global rank#7,663,681
among all websites
- Category rank#7,104
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.9
- Average visit41 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Britannia Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lipa.com.au | 100% | 6.5K | #2,944,886 | View details | |
| medapharma.us | 100% | View details | |||
galenus.gr | galenus.gr | 100% | – | ||
medicalresearchfoundation.org.uk | medicalresearchfoundation.org.uk | 89% | #2,182,733 | – | |
| carepharmaceuticals.com.au | 62% | 4.8K | #3,743,223 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Britannia Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Britannia Pharmaceuticals
Complete news archive for Britannia Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Britannia Pharmaceuticals
Britannia Pharmaceuticals was founded in 1981.
Britannia Pharmaceuticals is headquartered in Reading, United Kingdom.
Robert Wood is the CEO of Britannia Pharmaceuticals, as recorded in our data.
Britannia Pharmaceuticals has 96 employees.
Annual revenue of Britannia Pharmaceuticals is $90.92M as on Dec 31, 2020.
Britannia Pharmaceuticals Limited is engaged in the development and provision of innovative specialty therapies aimed at improving disease management and quality of life for patients with long-term neurological conditions such as Parkinsons disease and schizophrenia, as well as nephrology. The company is involved in funding clinical trials, supporting treatment programs, and investing in care initiatives for patients, families, and caregivers. Operating as part of the STADA Group, Britannia serves over 30 countries worldwide, delivering high-quality, ethical treatments and services across various therapeutic areas.
Britannia Pharmaceuticals offers Parkinson’s Disease Therapies, Schizophrenia Treatments, and Nephrology Solutions.
Britannia Pharmaceuticals operates through Britannia Pharmaceuticals Limited.